FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 776 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish... May 5, 2026 Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 Moving target – retrotransposable elements and cancer July 11, 2023 Tumors May Shed Protein to Create Barriers that Block Immune Cells December 10, 2021 Load more HOT NEWS The award-winning team transforming breast cancer treatment Breathing Amidst Uncertainty Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback Thanks For Making This GivingTuesday Our Best One Yet!
